Cargando…

Scalability of the Positive and Negative Syndrome Scale in first‐episode schizophrenia assessed by Rasch models

OBJECTIVE: Historically, assessment of the psychometric properties of the Positive and Negative Syndrome Scale (PANSS) has had several foci: (1) calculation of reliability indexes, (2) extraction of subdimensions from the scale, and (3) assessment of the validity of the total score. In this study, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baandrup, Lone, Allerup, Peter, Nielsen, Mette Ø., Düring, Signe W., Bojesen, Kirsten B., Leucht, Stefan, Galderisi, Silvana, Mucci, Armida, Bucci, Paola, Arango, Celso, Díaz‐Caneja, Covadonga M., Dazzan, Paola, McGuire, Philip, Demjaha, Arsime, Ebdrup, Bjørn H., Fleischhacker, Wolfgang W., Kahn, René S., Glenthøj, Birte Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325503/ https://www.ncbi.nlm.nih.gov/pubmed/35417039 http://dx.doi.org/10.1111/acps.13434

Ejemplares similares

Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: the OPTiMiSE study
por: Demjaha, Arsime, et al.
Publicado: (2023)

Prediction of drop-out and functional impairment in recent-onset schizophrenia spectrum disorders
por: Mucci, A., et al.
Publicado: (2021)

31.3 CLINICAL UTILITY OF MRI SCANNING IN FIRST EPISODE PSYCHOSIS
por: Dazzan, Paola, et al.
Publicado: (2018)

Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study
por: Martinuzzi, Emanuela, et al.
Publicado: (2019)

Correction: Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study
por: Martinuzzi, Emanuela, et al.
Publicado: (2019)

Cariprazine as a treatment for negative psychotic symptoms in first-episode psychosis: case series
por: Demjaha, Arsime, et al.
Publicado: (2022)

Effects of Blocking D2/D3 Receptors on Mismatch Negativity and P3a Amplitude of Initially Antipsychotic Naïve, First Episode Schizophrenia Patients
por: Düring, Signe, et al.
Publicado: (2015)

Circadian rest-activity rhythms during benzodiazepine tapering covered by melatonin versus placebo add-on: data derived from a randomized clinical trial
por: Baandrup, Lone, et al.
Publicado: (2016)

Clinical Course, Neurobiology and Therapeutic Approaches to Treatment Resistant Schizophrenia. Toward an Integrated View
por: Leung, Cheryl Cheuk-Yan, et al.
Publicado: (2019)

Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study
por: Galderisi, Silvana, et al.
Publicado: (2021)

Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial
por: Rasmussen, Jesper Østrup, et al.
Publicado: (2021)

Glutamate Levels and Resting Cerebral Blood Flow in Anterior Cingulate Cortex Are Associated at Rest and Immediately Following Infusion of S-Ketamine in Healthy Volunteers
por: Bojesen, Kirsten Borup, et al.
Publicado: (2018)

The Brief negative Symptom Scale (BNSS): a systematic review of measurement properties
por: Weigel, Lucia, et al.
Publicado: (2023)

Glyceryl trinitrate in first-episode psychosis unmedicated with antipsychotics: A randomised controlled pilot study
por: Merritt, Kate, et al.
Publicado: (2020)

T40. GLYCERYL TRINITRATE IN FIRST EPISODE PSYCHOSIS UNMEDICATED WITH ANTIPSYCHOTICS: A RANDOMISED CONTROLLED FEASIBILITY STUDY
por: Merritt, Kate, et al.
Publicado: (2020)

Gender Differences in Clinical and Psychosocial Features Among Persons With Schizophrenia: A Mini Review
por: Giordano, Giulia Maria, et al.
Publicado: (2021)

Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol
por: Ishøy, Pelle L, et al.
Publicado: (2014)

White matter microstructure and sleep-wake disturbances in individuals at ultra-high risk of psychosis
por: Rasmussen, Jesper Ø., et al.
Publicado: (2022)

Extreme deviations from the normative model reveal cortical heterogeneity and associations with negative symptom severity in first-episode psychosis from the OPTiMiSE and GAP studies
por: Worker, Amanda, et al.
Publicado: (2023)

Cognitive-enhancing effects of aripiprazole: a case report
por: Mucci, Armida, et al.
Publicado: (2008)

Frontal D(2/3) Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology
por: Nørbak-Emig, Henrik, et al.
Publicado: (2016)

M143. REGIONAL CEREBRAL BLOOD FLOW IN INITIALLY ANTIPSYCHOTIC-NAïVE PATIENTS WITH SCHIZOPHRENIA OR PSYCHOSIS: EFFECTS OF PARTIAL D2 RECEPTOR AGONISM AND ASSOCIATION WITH SYMPTOM IMPROVEMENT
por: Bojesen, Kirsten, et al.
Publicado: (2020)

Differential Effects of Aripiprazole and Amisulpride on Negative and Cognitive Symptoms in Patients With First-Episode Psychoses
por: Nielsen, Mette Ødegaard, et al.
Publicado: (2022)

Formal thought disorder in people at ultra-high risk of psychosis
por: Demjaha, Arsime, et al.
Publicado: (2017)

Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate
por: Merritt, Kate, et al.
Publicado: (2019)

Cerebral blood flow in striatum is increased by partial dopamine agonism in initially antipsychotic-naïve patients with psychosis
por: Bojesen, Kirsten Borup, et al.
Publicado: (2023)

Gender Differences in Neuropsychological Performance across Psychotic Disorders – a Multi-Centre Population Based Case-Control Study
por: Zanelli, Jolanta, et al.
Publicado: (2013)

Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol
por: Baltzersen, Olga B., et al.
Publicado: (2020)

Optimizing subjective wellbeing with amisulpride in first episode schizophrenia or related disorders
por: de Haan, Lieuwe, et al.
Publicado: (2023)

Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol
por: Baandrup, Lone, et al.
Publicado: (2011)

Oxidative Stress and Inflammation in Early Onset First Episode Psychosis: A Systematic Review and Meta-Analysis
por: Fraguas, David, et al.
Publicado: (2017)

Brain Connectivity Studies in Schizophrenia: Unravelling the Effects of Antipsychotics
por: Nejad, Ayna B, et al.
Publicado: (2012)

European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia
por: Vita, Antonio, et al.
Publicado: (2022)

Correlations between Negative Symptoms and Cognitive Deficits in Individuals at First Psychotic Episode or at High Risk of Psychosis: A Systematic Review
por: Melillo, Antonio, et al.
Publicado: (2023)

Socioeconomic status and severe mental disorders: a bidirectional multivariable Mendelian randomisation study
por: Andreu-Bernabeu, Álvaro, et al.
Publicado: (2023)

Negative Symptoms of Schizophrenia and Dopaminergic Transmission: Translational Models and Perspectives Opened by iPSC Techniques
por: Collo, Ginetta, et al.
Publicado: (2020)

Corrigendum: Negative Symptoms of Schizophrenia and Dopaminergic Transmission: Translational Models and Perspectives Opened by iPSC Techniques
por: Collo, Ginetta, et al.
Publicado: (2021)

Outcomes following first-episode psychosis – Why we should intervene early in all ages, not only in youth
por: Lappin, Julia M, et al.
Publicado: (2016)

European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter Study
por: Dollfus, Sonia, et al.
Publicado: (2022)

Cognitive Impairment after Post-Acute COVID-19 Infection: A Systematic Review of the Literature
por: Perrottelli, Andrea, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_noaep8sm70oikv52fr7dpo3ekl